



Press release

SHL appoints Yoav Rubinstein as CEO

Tel Aviv / Zurich, 2 June 2017 – SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN, OTCPK: SMDCY) (“SHL”), a leading provider and developer of advanced personal telemedicine solutions, announced today that Yoav Rubinstein, its interim acting CEO since April this year, will become the company’s new CEO, effective immediately.

The Board of Directors has unanimously agreed for Yoav Rubinstein to become CEO of SHL and is looking forward to working with him and the entire management team to lead SHL into a new phase of growth. Being with the company for more than five years, Yoav Rubinstein has a very good knowledge of SHL which, paired with his management experience as a business developer and in the private equity industry, and his outstanding capabilities, is of high value to SHL.

Mr. Rubinstein thanked the Board for the vote of confidence and said he was looking forward to the challenge of working together with the Board and contributing to SHL’s stability and success.

Yoav Rubinstein joined SHL in 2012 as Senior Vice President, Head of Global Business Development. In April 2017, he was appointed interim acting CEO of SHL. Before joining SHL, Yoav Rubinstein worked in the private equity industry, for ten years as a Principal for Apax Partners and then as a Senior Advisor to Saban Capital Group. Mr. Rubinstein holds a BA in Business Administration from the Interdisciplinary Center, Israel. Nationality: Israeli and American.

For further information, please contact:

Martin Meier-Pfister, IRF Communications, phone: +41 43 244 81 40, shl@irfcom.ch

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and has an ADR program listed over-the counter; Symbol: SMDCY. For more information, please visit the web site at www.shl-telemedicine.com.

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.